GT200600123A - DERIVATIVES OF TETRAHYDRONAFTALINE, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS AN INFLAMMATION INHIBITOR - Google Patents

DERIVATIVES OF TETRAHYDRONAFTALINE, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS AN INFLAMMATION INHIBITOR

Info

Publication number
GT200600123A
GT200600123A GT200600123A GT200600123A GT200600123A GT 200600123 A GT200600123 A GT 200600123A GT 200600123 A GT200600123 A GT 200600123A GT 200600123 A GT200600123 A GT 200600123A GT 200600123 A GT200600123 A GT 200600123A
Authority
GT
Guatemala
Prior art keywords
procedures
derivatives
preparation
tetrahydronaftaline
inflammation inhibitor
Prior art date
Application number
GT200600123A
Other languages
Spanish (es)
Inventor
Markus Berger
Stefan Baurle
Heike Schacke
Hartmut Rehwinkel
Norbert Schmees
Bernd Buchmann
Konrad Krolikiewicz
Anne Mengel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600123A publication Critical patent/GT200600123A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring

Abstract

ESTA INVENCIÓN PRESENTA DERIVADOS DE TETRAHIDRONAFTALINA DE LA FÓRMULA GENERAL (I), LOS PROCEDIMIENTOS PARA SU PREPARACIÓN, COMPOSICIONES FARMACÉUTICS Y SU USO COMO INHIBIDORES DE LA INFLAMACIÓN.THIS INVENTION PRESENTS DERIVATIVES OF TETRAHIDRONAFTALINA OF THE GENERAL FORMULA (I), THE PROCEDURES FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS AND ITS USE AS INFLAMMATION INHIBITORS.

GT200600123A 2005-03-22 2006-03-21 DERIVATIVES OF TETRAHYDRONAFTALINE, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS AN INFLAMMATION INHIBITOR GT200600123A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005014089A DE102005014089A1 (en) 2005-03-22 2005-03-22 Tetrahydronaphthalene derivatives, process for their preparation and their use as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
GT200600123A true GT200600123A (en) 2007-01-03

Family

ID=36481394

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600123A GT200600123A (en) 2005-03-22 2006-03-21 DERIVATIVES OF TETRAHYDRONAFTALINE, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS AN INFLAMMATION INHIBITOR

Country Status (11)

Country Link
EP (1) EP1861379A1 (en)
JP (1) JP2008534463A (en)
CN (1) CN101146779A (en)
AR (1) AR056949A1 (en)
CA (1) CA2598205A1 (en)
DE (1) DE102005014089A1 (en)
GT (1) GT200600123A (en)
PE (1) PE20061362A1 (en)
TW (1) TW200716564A (en)
UY (1) UY29434A1 (en)
WO (1) WO2006100100A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
ES2279454T3 (en) 2003-10-08 2007-08-16 Bayer Schering Pharma Aktiengesellschaft DERIVATIVES OF TETRAHYDRONAFTALENE SUBSTITUTED WITH 1-AMINO-2-OXI, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS ANTI-INFLAMMATORY.
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20080153859A1 (en) 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
EP1834948A1 (en) * 2006-03-15 2007-09-19 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiinflammatory drugs
EP2072509A1 (en) 2007-12-18 2009-06-24 Bayer Schering Pharma Aktiengesellschaft 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents
CN101768086B (en) * 2008-12-29 2014-03-26 北京富龙康泰生物技术有限公司 Amino methanol derivant and salt compound thereof as well as synthesizing method and medical application thereof
EP2459524A2 (en) 2009-07-31 2012-06-06 Cadila Healthcare Limited Novel compounds as modulators of glucocorticoid receptors
JP6115303B2 (en) * 2012-05-18 2017-04-19 Jnc株式会社 Phenol compound having carbonyl group as adjacent group and use thereof
EP3109237A1 (en) 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
AU2020311940A1 (en) 2019-07-11 2022-02-03 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ224622A (en) * 1987-05-15 1992-06-25 Schering Corp Benzoxepine, benzazepine and benzocycloheptene derivatives and pharmaceutical compositions
EP0299470B1 (en) * 1987-07-16 1996-12-04 Byk Gulden Lomberg Chemische Fabrik GmbH Imidazo[1,2-a]pyridines
US5489584A (en) * 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
DE10038639A1 (en) * 2000-07-28 2002-02-21 Schering Ag New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism

Also Published As

Publication number Publication date
AR056949A1 (en) 2007-11-07
TW200716564A (en) 2007-05-01
DE102005014089A1 (en) 2006-09-28
WO2006100100A1 (en) 2006-09-28
PE20061362A1 (en) 2006-12-20
CA2598205A1 (en) 2006-09-28
JP2008534463A (en) 2008-08-28
CN101146779A (en) 2008-03-19
EP1861379A1 (en) 2007-12-05
UY29434A1 (en) 2006-10-02

Similar Documents

Publication Publication Date Title
GT200600123A (en) DERIVATIVES OF TETRAHYDRONAFTALINE, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS AN INFLAMMATION INHIBITOR
CL2008002430A1 (en) Benzenesulfonamide derived compounds, cathepsin c inhibitors; pharmaceutical composition comprising them; and its use for the treatment of copd.
CR11618A (en) SERINA PROTEASA MACROCYCLIC INHIBITORS
UY29213A1 (en) DERIVATIVES OF QUINOLIN AND ISOQUINOLINE 5-SUSTITIUED, A PROCEDURE FOR THEIR PREPARATION AND ITS USE AS INFLAMMATION INHIBITORS
ECSP099721A (en) KINASE INHIBITORS P70 S6
UY30748A1 (en) NEW COMPOUNDS
CL2007002166A1 (en) Compounds derived from nitrogen heterocycles, antagonists of apoptosis protein inhibitors; its pharmaceutical compositions; and use of said compounds for the treatment of cancer.
DOP2006000193A (en) ISOINDOL-IMIDA COMPOUNDS AND COMPOSITIONS INCLUDING THEM AND METHODS FOR USE
SV2010003559A (en) SOME DERIVATIVES OF 2-PIRAZINONA AND ITS USE AS INHIBITORS OF ELASTASA DE LOS NEUTROFILOS
CO6321282A2 (en) PIPERIDINYLINDOL DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA
CR20110028A (en) PIRIMIDINE DERIVATIVES AS CINASE INHIBITORS
ECSP077271A (en) PIRIMIDINE DERIVATIVES
CL2011000691A1 (en) Compounds derived from substituted nicotinamide; pharmaceutical composition that includes them; use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
CL2009000426A1 (en) Compounds derived from carbocyclyl / heterocyclyl-pyridin-2-yl-urea, bacterial topoisomerase iv inhibitors; pharmaceutical composition; and its use for the treatment of bacterial infections
NI201000041A (en) DERIVATIVES AND COMPOSITIONS INCLUDING QUINAZOLINONE 6-, 7-, OR 8 - SUBSTITUTE AND METHODS TO USE THE SAME
ECSP077259A (en) PIRIMIDINE DERIVATIVES
ECSP088800A (en) DPP IV inhibitor formulations
CL2007003100A1 (en) COMPOUNDS DERIVED FROM PIRIMIDINA, INHIBITORS OF CISTEINE PROTEASA; PREPARATION PROCESSES; SALES OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF MALARIA.
NI201000055A (en) 2 '- FLUORO - 2' - DEOXYTETHYDROURIDINES AS INHIBITORS OF CITIDINE DESAMINE.
UY30846A1 (en) OXINDOL DERIVATIVES REPLACED, MEDICINES THAT UNDERSTAND AND USE THEMSELVES
ECSP088288A (en) DERIVATIVES OF 7- (2-AMINO-1-HIDROXI-ETIL) -4-HYDROXIBENZOTIAZOL-2 (3H) -ONA AS AGONISTS OF ADRENOCEPTORS ß2
GT200800187A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINE COMPOUNDS AND PROCEDURES FOR THE SAME USE
GT200900192A (en) IMIDAZOL DERIVATIVES AS PROTEIN INHIBITORS FOR THE USE OF CINESINE (EG-5) .-
GT200600366A (en) IMIDAZOL COMPOUNDS REPLACED AS KSP INHIBITORS
SV2009003212A (en) METALOPROTEASE INHIBITORS DERIVED FROM HETEROCICLICS REF. PRD2727SVPCT